SCHEMBL210356

SCHEMBL210356

COc1cc2nc(SCc3ccc(C(=O)O)cc3)[nH]c2cc1OC

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2E1 P05181 9/20 0.74
CYP2C8 P10632 9/20 0.74
CYP2D6 P10635 9/20 0.74
CYP2C9 P11712 9/20 0.74
CYP2B6 P20813 9/20 0.74
CYP2C19 P33261 9/20 0.74
CYP3A4 P08684 8/20 0.74
CYP1A2 P05177 7/20 0.74
ALOX5 P09917 1/20 0.65
EPHX2 P34913 1/20 0.57
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
POLB P06746 2/20 0.50
HDAC1 Q13547 1/20 0.50
HPGD P15428 1/20 0.50
PTBP1 P26599 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NPC1 O15118 1/20 0.49
NFKB1 P19838 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1065421 0.85 CYP2E1 (0.83) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL2734131 0.85 CYP2E1 (1.00) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL210929 0.82 ALOX5 (0.72) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL210720 0.80 HDAC1 (0.79) ALDH1A1SMN1; SMN2POLBHDAC1HPGD
SCHEMBL210572 0.79 ALOX5 (0.61) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL8291917 0.78 ALOX5 (0.64) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL211295 0.78 ALOX5 (0.67) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL10691877 0.78 ALDH1A1 (0.75) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL1063187 0.75 CYP2E1 (0.68) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL1064755 0.75 CYP2E1 (0.82) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
EP-1735319-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-12-27 EP disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 CYP2E1 4419/4885CYP2C8 4381/4885CYP2D6 4578/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 CYP2E1 4542/4885CYP2C8 4584/4885CYP2D6 4665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.